Alnylam Pharmaceuticals Files Proxy Materials
Ticker: ALNY · Form: DEFA14A · Filed: Mar 24, 2025 · CIK: 1178670
Sentiment: neutral
Topics: proxy-filing, regulatory
Related Tickers: ALNY
TL;DR
ALNY proxy filing is in, no fee needed. Vote counts!
AI Summary
Alnylam Pharmaceuticals, Inc. filed a Definitive Additional Materials proxy statement on March 24, 2025. This filing is related to the company's proxy statement and indicates that no filing fee was required for this submission. The company is headquartered in Cambridge, MA.
Why It Matters
This filing is a routine regulatory submission for Alnylam Pharmaceuticals, providing shareholders with information related to upcoming votes or corporate actions.
Risk Assessment
Risk Level: low — This is a standard regulatory filing (DEFA14A) with no immediate financial implications or new disclosures of risk.
Key Players & Entities
- ALNYLAM PHARMACEUTICALS, INC. (company) — Registrant
- 0001193125-25-061424 (filing_id) — Accession Number
- 20250324 (date) — Filing Date
- 675 WEST KENDALL STREET (address) — Business Address
- CAMBRIDGE (city) — Business Location
- MA (state) — Business Location
- 02142 (zip_code) — Business Location
FAQ
What type of filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
Who is the filing company?
The filing company is Alnylam Pharmaceuticals, Inc.
When was this filing submitted?
The filing was submitted on March 24, 2025.
Was there a fee required for this filing?
No fee was required for this filing, as indicated by the checked box 'No fee required'.
Where is Alnylam Pharmaceuticals, Inc. located?
Alnylam Pharmaceuticals, Inc. is located at 675 West Kendall Street, Cambridge, MA 02142.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on March 24, 2025 regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).